HTG’s Technology to be Featured at D2D Conference
Complete the form below to unlock access to ALL audio articles.
HTG has announced that its' ArrayPlate qNPAT technology will be featured in a presentation examining retrospective validation of gene signature biomarkers at IBC's Discovery 2 Diagnostics (D2D) Conference and Exhibition taking place from September 25-27 in Boston, Mass.
Tom Grogan, M.D. will describe how, until now, measuring gene expression quantitatively in fixed tissue samples has been difficult and cumbersome. Conventional methods yield limited results.
Using HTG's ArrayPlate qNPAT technology, Grogan conducted retrospective gene expression studies and validated a biomarker signature for predicting survival of patients with Diffuse Large B Cell Lymphoma, the most common of the non-Hodgkin's lymphomas, accounting for up to 30 percent of newly diagnosed cases.
Grogan's work addresses a controversy between two, non-overlapping signatures described in the literature.
Who: Tom Grogan, M.D., Professor, University of Arizona, Department of Pathology and Chief Scientific Officer and Founder, Ventana Medical
What: "Retrospective Validation of Gene Signature Biomarkers for Diffuse Large B Cell Lymphoma Using the ArrayPlate qNPAT and Matched Frozen and Fixed Tissue"
When: Wednesday, September 27, 2006, 11:15 a.m.
Where: Exhibition Hall, Hynes Convention Center, Boston, Mass.
HTG will be located at Booth # 510 at the conference.
